Arch Therapeutics (ARTH) 10-Q 14 Feb 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Dec. 31, 2022	Feb. 14, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	000-54986
Entity Registrant Name	ARCH THERAPEUTICS, INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	46-0524102
Entity Address, Address Line One	235 Walnut Street, Suite 6
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01702
City Area Code	617
Local Phone Number	431-2313
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		1,262,513
Entity Central Index Key	0001537561
Current Fiscal Year End Date	--09-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Current assets:
Cash	$ 10,618	$ 746,940
Inventory	1,411,637	1,414,848
Prepaid expenses and other current assets	288,915	436,407
Total current assets	1,711,170	2,598,195
Long-term assets:
Property and equipment, net	1,381	2,044
Other assets	3,500	3,500
Total long-term assets	4,881	5,544
Total assets	1,716,051	2,603,739
Current liabilities:
Accounts payable	1,761,482	1,328,000
Accrued expenses and other liabilities	255,309	318,505
Current portion of accrued interest	238,425	127,781
Current portion of derivative liability	748,275	748,275
Total current liabilities	4,145,167	3,320,494
Senior secured and unsecured convertible notes, net of discount and issuance costs		2,362,273
Accrued interest	246,489	204,575
Derivative liability	459,200	459,200
Total long-term liabilities	3,459,717	3,476,048
Total liabilities	7,604,884	6,796,542
Commitments and Contingencies
Stockholders’ equity (deficit):
Common stock, $0.001 par value, 4,000,000 shares authorized as of December 31, 2022 and September 30, 2022, 1,249,682 shares, issued as of December 31, 2022 and September 30, 2022, and 1,249,432 outstanding as of December 31, 2022 and September 30, 2022	1,249	1,249
Additional paid-in capital	50,982,747	50,878,721
Accumulated deficit	(56,872,829)	(55,072,773)
Total stockholders’ deficit	(5,888,833)	(4,192,803)
Total liabilities and stockholders’ deficit	1,716,051	2,603,739
Insurance Premium Financing [Member]
Current liabilities:
Insurance premium financing	141,676	247,933
Convertible Notes Payable Series One [Member]
Current liabilities:
Current portion of Series convertible notes	550,000	550,000
Convertible Notes Payable Series Two [Member]
Current liabilities:
Current portion of Series convertible notes	450,000
Series convertible notes	0	$ 450,000
Senior Secured Convertible Notes [Member]
Current liabilities:
Senior secured and unsecured convertible notes, net of discount and issuance costs	$ 2,754,028

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)	Dec. 31, 2022 $ / shares shares
Common Stock, Par Value (in dollars per share) | $ / shares	$ 0.001
Common Stock, Shares Authorized (in shares)	4,000,000
Common stock, shares issued (in shares)	1,249,682
Common Stock, Shares, Outstanding, Ending Balance (in shares)	1,249,432

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue	$ 6,261	$ 4,696
Operating expenses:
Cost of revenues	17,635	16,792
Selling, general and administrative expenses	1,102,916	1,263,104
Research and development expenses	161,453	234,618
Total costs and expenses	1,282,004	1,514,514
Loss from operations	(1,275,743)	(1,509,818)
Other expense:
Interest expense	(524,313)	(40,329)
Total other expense	(524,313)	(40,329)
Net loss	$ (1,800,056)	$ (1,550,147)
Loss per share - basic and diluted
Net loss per common share - basic and diluted (in dollars per share)	$ (1.44)	$ (1.31)
Weighted common shares - basic and diluted (in shares)	1,249,432	1,183,946

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Sep. 30, 2021	1,183,599
Balance at Sep. 30, 2021	$ 1,184	$ 48,770,061	$ (49,796,919)	$ (1,025,674)
Net loss			(1,550,147)	(1,550,147)
Stock-based compensation expense		152,143		152,143
Vesting of Restricted Stock (in shares)	375
Vesting of Restricted Stock	$ 0	0		0
Balance (in shares) at Dec. 31, 2021	1,183,974
Balance at Dec. 31, 2021	$ 1,184	48,922,204	(51,347,066)	(2,423,678)
Balance (in shares) at Sep. 30, 2022	1,249,432
Balance at Sep. 30, 2022	$ 1,249	50,878,721	(55,072,773)	(4,192,803)
Net loss	$ 0	0	(1,800,056)	(1,800,056)
Stock-based compensation expense		104,026	0	104,026
Balance (in shares) at Dec. 31, 2022	1,249,432
Balance at Dec. 31, 2022	$ 1,249	$ 50,982,747	$ (56,872,829)	$ (5,888,833)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (1,800,056)	$ (1,550,147)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	663	799
Stock-based compensation	104,026	152,143
Accretion of discount and debt issuance costs on 2022 Notes	371,755	0
Changes in operating assets and liabilities:
Inventory	3,211	375
Prepaid expenses and other current assets	147,492	(46,886)
Accounts payable	433,482	340,797
Accrued interest	152,558	40,329
Accrued expenses and other liabilities	(63,196)	(115,935)
Net cash used in operating activities	(650,065)	(1,178,525)
Cash flows from financing activities:
Repayment of insurance premium financing	(106,257)	0
Proceeds received from second closing of the convertible notes	20,000	0
Net cash used in financing activities	(86,257)	0
Net decrease in cash	(736,322)	(1,178,525)
Cash, beginning of year	746,940	2,266,639
Cash, end of period	$ 10,618	$ 1,088,114

Note 1 - Description of Busines

Note 1 - Description of Business	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. BASIS OF PRESENTATION AND DESCRIPTION OF BUSINESS Organization and Description of Business Arch Therapeutics, Inc. (together with its subsidiary, the “ Company Arch Merger ABS Merger Sub ABS was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006, as Clear Nano Solutions, Inc. On April 7, 2008, ABS changed its name from Clear Nano Solutions, Inc. to Arch Therapeutics, Inc. Effective upon the closing of the Merger, ABS changed its name from Arch Therapeutics, Inc. to Arch Biosurgery, Inc. In the first quarter of 2021, the Company commenced commercial sales of our first product, AC5® Advanced Wound System, and has devoted substantially all of the Company’s operational effort to the research, development and regulatory programs necessary to turn the Company’s core technology into commercial products. To date, the Company has principally raised capital through the issuance of convertible debt, and the issuance of units consisting of its common stock, $0.001 par value per share (“ Common Stock warrants The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential future products. However, there can be no assurance that the Company will be successful in securing additional resources when needed, on terms acceptable to the Company, if at all. Therefore, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments related to the recoverability of assets that might be necessary despite this uncertainty.

Note 2 - Summary Of Significant

Note 2 - Summary Of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Although the Company believes that the disclosures in these unaudited interim consolidated financial statements are adequate to make the information presented not misleading, certain information normally included in the footnotes prepared in accordance with US GAAP has been omitted as permitted by the rules and regulations of the Securities and Exchange Commission (“ SEC Annual Report For a complete summary of the Company’s significant accounting policies, please refer to Note 2 included in Item 8 of the Company’s Annual Report. There have been no material changes to the Company’s significant accounting policies during the three months ended December 31, 2022. Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. On January 6, 2023, the directors of the Company authorized a reverse share split of the issued and outstanding Common Shares in a ratio of 200:1, effective January 17, 2023 (the “ Reverse Share Split Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents as of December 31, 2022 and September 30, 2022. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash. Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not be recoverable in accordance with the Financial Accounting Standards Board (“ FASB ASC Property, Plant and Equipment Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s lease does not provide an implicit interest rate, the Company used an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Income Taxes In accordance with FASB ASC Topic 740, Income Taxes The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not that a loss will be incurred related to these matters and the amount of the loss is reasonably determinable. Revenue In accordance with FASB ASC Topic 606, Revenue Recognition The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third-party warehouse. Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation ASC 718 Black-Scholes Model The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718-10-S99, and the contractual term for all other employee and non-employee awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the Company’s awards. The dividend yield assumption is based on history and the expectation of paying no dividends. Stock-based compensation expense, when recognized in the consolidated financial statements, is based on awards that are ultimately expected to vest. Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures At December 31, 2022 and September 30, 2022, the carrying amounts of cash, accounts payables and accrued expense and other liabilities approximate fair value because of their short-term nature. The carrying amounts for the Convertible Notes (See Note 12) approximate fair value because borrowing rates and term are similar to comparable market participants. Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging ASC 815 Complex Financial Instruments The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates its financial instruments, including warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. The Company values its derivatives using the Black-Scholes option-pricing model or other acceptable valuation models, including Monte-Carlo simulations. Derivative instruments are valued at inception, upon events such as an exercise of the underlying financial instrument, and at subsequent reporting periods. The classification of derivative instruments, including whether such instruments should be recorded as liabilities, is re-assessed at the end of each reporting period. The Company reviews the terms of debt instruments, equity instruments, and other financing arrangements to determine whether there are embedded derivative features, including embedded conversion options that are required to be bifurcated and accounted for separately as a derivative financial instrument. Additionally, in connection with the issuance of financing instruments, the Company may issue freestanding options and warrants, including options or warrants to non-employees in exchange for consulting or other services performed. The Company accounts for its common stock warrants in accordance with Accounting Standards Codification (“ASC”) 815, Derivatives and Hedging Subsequent Events The Company evaluated all events or transactions through February 14, 2023, the date which these consolidated financial statements were issued. Please note 14 for matters deemed to be subsequent events. Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit as of December 31, 2022, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product and eventually attaining and maintaining profitable operations. In particular, as of December 31, 2022, the Company will be required to raise additional capital, obtain alternative means of financial support, or both, in order to continue to fund operations, and therefore there is substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenses into the foreseeable future for the research, development and commercialization of its current and potential products. In addition, the Company will require additional financing in order to seek to license or acquire new assets, research and develop any potential patents and the related compounds, and obtain any further intellectual property that the Company may seek to acquire. Finally, some of our product candidates or the materials contained therein (such as the Active Pharmaceutical Ingredients for our AC5® product line), are manufactured from facilities in areas impacted by the outbreak of the COVID-19, which could result in shortages due to ongoing efforts to address the outbreak. Historically, the Company has principally funded operations through debt borrowings, the issuance of convertible debt, and the issuance of units consisting of common stock and warrants. Provisions in the Securities Purchase Agreements that the Company entered into on June 28, 2018 (“ 2018 SPA 2022 SPA The 2021 SPA contains certain restrictions on our ability to conduct subsequent sales of our equity securities (See Note 10). The continued spread of COVID-19 and uncertain market conditions may also limit the Company’s ability to access capital. If the Company is unable to obtain adequate capital, the Company may be required to reduce the scope, delay, or eliminate some or all of its planned activities. These conditions, in the aggregate, raise substantial doubt as to the Company’s ability to continue as a going concern. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments that might result from this uncertainty.

Note 3 - Property and Equipment

Note 3 - Property and Equipment	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. PROPERTY AND EQUIPMENT At December 31, 2022 and September 30, 2022, property and equipment consisted of: Estimated Useful Life (in years) December 31 2022 September 30, 2022 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 32,375 31,712 Property and equipment, net $ 1,381 $ 2,044 For the three months ended December 31, 2022 and 2021, depreciation expense recorded was $663 and $799, respectively.

Note 4 - Inventories

Note 4 - Inventories	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	4 INVENTORIES Inventories consist of the following: December 31, September 30, 2022 2022 Finished Goods $ 85,526 $ 9,063 Goods-in-process 1,326,111 1,405,785 Total $ 1,411,637 $ 1,414,848 The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not the inventory has a future economic benefit requires estimates by management. To the extent that inventory is expected to expire prior to being sold or used for research and development or used for samples, the Company will write down the value of inventory. In evaluating the net realizable value of the inventory, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors.

Note 5 - Insurance Premium Fina

Note 5 - Insurance Premium Financing	3 Months Ended
	Dec. 31, 2022
Insurance Premium Financing [Member]
Notes to Financial Statements
Short-Term Debt [Text Block]	5. INSURANCE PREMIUM FINANCING In July 2022, the Company entered into a finance agreement with First Insurance Funding in order to fund a portion of its insurance policies. The amount financed is approximately $354,000 and incurs interest at a rate of 2.99%. The Company is required to make monthly payments of approximately $35,000 through April 2023. The outstanding balance as of December 31, 2022 and September 30, 2022 was approximately $ 142,000 248,000

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	6. STOCK-BASED COMPENSATION 2013 Stock Incentive Plan On June 18, 2013, the Company established the 2013 Stock Incentive Plan (the “ 2013 Plan Board The exercise price of each option is equal to the closing price of a share of the Company’s Common Stock on the date of grant. Share-Based Awards During the three months ended December 31, 2022, the Company awarded 20,875 options to employees and directors and 3,625 options to consultants to purchase shares of Common Stock under the 2013 Plan . Share-based compensation expense for awards granted during the three months ended December 31, 2022 was based on the grant date fair value estimated using the Black-Scholes Model. Common Stock Options Stock compensation activity under the 2013 Plan for the three months ended December 31, 2022 follows: Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2022 98,626 $ 52.00 1.46 $ 16,900 Awarded 24,500 $ 6.00 Forfeited/Cancelled (18,801 ) $ 70.00 Outstanding at December 31, 2022 104,325 $ 40.00 1.26 3,900 Vested at December 31, 2022 68,202 $ 54.00 1.50 975 Vested and expected to vest at December 31, 2022 104,325 $ 40.00 1.26 3,900 As of December 31, 2022, 50,667 shares are available for future grants under the 2013 Plan. Share-based compensation expense recorded in the Company’s Consolidated Statements of Operations for the three months ended December 31, 2022 and 2021 resulting from options awarded to the Company’s employees, directors and consultants was approximately $102,000 and $142,000, respectively. Of this amount, during the three months ended December 31, 2022 and 2021, $14,000 and $53,000, respectively, were recorded as research and development expense, and $88,000 and $89,000, respectively were recorded as general and administrative expense in the Company’s Consolidated Statements of Operations. During the three months ended December 31, 2022 and 2021, no options awarded were exercised. As of December 31, 2022, there is approximately $295,000 of unrecognized compensation expense related to unvested stock-based compensation arrangements granted under the 2013 Plan. That cost is expected to be recognized over a weighted average period of 3.02 years. Restricted Stock Restricted stock activity under the 2013 Plan for the three months ended December 31, 2022 and 2021, in shares, follows: Three months Ended December 31, 2022 December 31, 2021 Non Vested at September 30, 2022 and 2021 250 2,250 Vested - (375 ) Non Vested at December 31, 2022 and 2021 250 1,875 The weighted grant date fair value average of the restricted stock for the three months ended December 31, 2022 and 2021 follows: Three months Ended December 31, 2022 December 31, 2021 Non Vested at September 30, 2022 and 2021 $ 18.00 $ 20.00 Vested - (20.00 ) Non Vested at December 31, 2022 and 2021 $ 18.00 $ 20.00 For the three months ended December 31, 2022 and 2021, compensation expense recorded for the restricted stock awards was approximately $2,000 and $10,000, respectively.

Note 7 - Registered Direct Offe

Note 7 - Registered Direct Offerings	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. REGISTERED DIRECT OFFERINGS On September 30, 2016, the Company filed a registration statement with the SEC utilizing a “shelf” registration process, which was subsequently declared effective by the SEC on October 20, 2016 (such registration statement, the “ Shelf Registration Statement On February 20, 2017, the Company entered into a Securities Purchase Agreement (the “ 2017 2017 Investors 2017 Financing Series F Warrant 2017 Warrants 2017 Warrant Shares On June 28, 2018, the Company entered into a Securities Purchase Agreement (“ 2018 SPA eight 2018 Investors 2018 Financing Series G Warrant 2018 Warrants 2018 Warrant Shares On May 12, 2019, the Company entered into a Securities Purchase Agreement (“ 2019 SPA five 2019 Investors 2019 Financing Series H Warrant 2019 Warrants 2019 2019 Warrant Shares During the three months ended December 31, 2022 and 2021, no Series F, Series G and Series H Warrants had been exercised. As of December 31, 2022, up to 34,013 and 43,077 shares may be acquired upon the exercise of the Series G and Series H Warrants, respectively. All 27,958 remaining Series F Warrants expired during the fiscal year ended September 30, 2022.

Note 8 - Derivative Liabilities

Note 8 - Derivative Liabilities	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	8. Derivative Liabilities The Company accounted for the Series F Warrants, Series G Warrants and the Series H Warrants in accordance with ASC 815-10. Since the Company may be required to purchase its Series F Warrants, Series G Warrants and Series H Warrants for an amount of cash equal to $36.00, $22.00 and $10.66, respectively, for each share of Common Stock ("Minimum") they are recorded as liabilities at the greater of the Minimum or fair value. They are marked to market each reporting period through the Consolidated Statement of Operations. On the respective closing dated, the derivative liabilities related to the Series G Warrants and Series H Warrants were recorded at an aggregate fair value of $1,628,113. Given that the fair value of the derivative liabilities was less than the net proceeds, the remaining proceeds were allocated to Common Stock and additional paid-in-capital. During the three months ended December 31, 2022 and 2021, $0 was recorded to decrease the fair value of derivative liability. As of December 31, 2022 and 2021, the derivative liabilities are recorded at their minimum value. Fair Value Measurements Using Significant Unobservable Inputs Three Months Ended December 31, 2022 (Level 3) Series G Series H Beginning balance at September 30, 2022 $ 748,275 $ 459,200 Adjustments to estimated fair value — — Ending balance at December 31, 2022 $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs - Three Months Ended December 31, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Issuances — — — Adjustments to estimated fair value — — — Ending balance at December 31, 2021 $ 1,000,000 $ 748,275 $ 459,200 The derivative liabilities as of December 31, 2022 are valued at the greater of their minimum value or by using the Black Scholes Model with the following assumptions. As of December 31, 2022, the derivative liabilities are recorded at their minimum value. Series G Series H Closing price per share of Common Stock $ 5.20 $ 5.20 Exercise price per share $ 140.00 $ 80.00 Expected volatility 169.62 % 138.58 % Risk-free interest rate 4.76 % 4.57 % Dividend yield — — Remaining expected term of underlying securities (years) 0.43 1.31 The derivative liabilities as of September 30, 2022 are valued at the greater of their minimum value or by using the Black Scholes Model with the following assumptions. As of September 30, 2022, the derivative liabilities are recorded at their minimum value. Series G Series H Closing price per share of Common Stock $ 3.80 $ 3.80 Exercise price per share $ 140.00 $ 80.00 Expected volatility 132.97 % 122.50 % Risk-free interest rate 4.05 % 4.14 % Dividend yield — — Remaining expected term of underlying securities (years) 0.69 1.57

Note 9 - October 2019 Registere

Note 9 - October 2019 Registered Direct Offering	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders Equity Note Direct Offering 2019 October [Text Block]	9. OCTOBER 2019 REGISTERED DIRECT OFFERING On October 16, 2019, (the “ October ”) October October Financing one Series I Warrant five The gross proceeds to the Company from the October 2019 Financing, which were received as of October 18, 2019, were approximately $2.5 million before deducting financing costs of approximately $333,000 which includes approximately $158,000 of placement fees. The number of shares of the Company’s Common Stock into which each of the Series I Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series I Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). The Company engaged H.C. Wainwright as its exclusive institutional investor placement agent (the “ Placement Agent 2019 Engagement Agreement During the three months ended December 31, 2022 and 2021, no Series I Warrants or Placement Agent Warrants were exercised. As of December 31, 2022, up to 71,429 and 5,358 shares may be acquired upon the exercise of the Series I Warrants and Placement Agent Warrants, respectively. Common Stock On October 18, 2019, the Closing Date of the October 2019 Financing, the Company issued 71,429 shares of Common Stock. Equity Value of Warrants The Company accounted for the Series I Warrants and the Placement Agent Warrants relating to the aforementioned October 2019 Financing in accordance with ASC 815-40. Because the Series I Warrants and the Placement Agent Warrants are indexed to the Company’s Common Stock, they are classified within stockholders’ deficit in the accompanying consolidated financial statements.

Note 10 - 2021 Registered Direc

Note 10 - 2021 Registered Direct Offering	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7. REGISTERED DIRECT OFFERINGS On September 30, 2016, the Company filed a registration statement with the SEC utilizing a “shelf” registration process, which was subsequently declared effective by the SEC on October 20, 2016 (such registration statement, the “ Shelf Registration Statement On February 20, 2017, the Company entered into a Securities Purchase Agreement (the “ 2017 2017 Investors 2017 Financing Series F Warrant 2017 Warrants 2017 Warrant Shares On June 28, 2018, the Company entered into a Securities Purchase Agreement (“ 2018 SPA eight 2018 Investors 2018 Financing Series G Warrant 2018 Warrants 2018 Warrant Shares On May 12, 2019, the Company entered into a Securities Purchase Agreement (“ 2019 SPA five 2019 Investors 2019 Financing Series H Warrant 2019 Warrants 2019 2019 Warrant Shares During the three months ended December 31, 2022 and 2021, no Series F, Series G and Series H Warrants had been exercised. As of December 31, 2022, up to 34,013 and 43,077 shares may be acquired upon the exercise of the Series G and Series H Warrants, respectively. All 27,958 remaining Series F Warrants expired during the fiscal year ended September 30, 2022.
The 2021 Registered Direct Offering [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. 2021 REGISTERED DIRECT OFFERING On February 11, 2021, the Company entered into a Securities Purchase Agreement (the “ 2021 SPA 2021 Investors Series K Warrants Warrant Shares 2021 Financing 2021 Engagement Agreement Placement Agent Warrants The 2021 SPA contained certain restrictions on the Company’s ability to conduct subsequent sales of the Company’s equity securities. In particular, we were prohibited from entering into or effecting a Variable Rate Transaction (as defined in the 2021 SPA) until February 11, 2022; provided, however, the Company may enter into and effect an at-the-market offering facility with the Placement Agent. The number of shares of the Company’s Common Stock into which each of the Series K Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series K Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). During the three months ended December 31, 2022, no Series K Warrants or Placement Agent 2 Warrants were exercised. As of December 31, 2022, up to 161,719 and 16,172 shares may be acquired upon the exercise of the Series K Warrants and Placement Agent Warrants, respectively. Common Stock On February 17, 2021, the Closing Date of the 2021 Financing, the Company issued 215,625 shares of Common Stock. Equity Value of Warrants The Company accounted for the Series K Warrants and the Placement Agent 2 Warrants relating to the aforementioned February 2021 Registered Direct Offering in accordance with ASC 815-40, Derivatives and Hedging

Note 11 - 2022 Convertible Note

Note 11 - 2022 Convertible Note Offering	3 Months Ended
	Dec. 31, 2022
Notes 2022 [Member]
Notes to Financial Statements
Debt Disclosure [Text Block]	11. 2022 CONVERTIBLE NOTE OFFERING On July 7, 2022, the Company announced that it had entered into a Securities Purchase Agreement (the “ 2022 SPA 2022 Investors 2022 Note 2022 Notes 2022 Warrants 2022 Warrant Shares 2022 Inducement Shares 2022 Note Offering 2022 Closing Date The 2022 Notes bear interest on the unpaid principal balance at a rate equal to ten percent (10%) (computed on the basis of the actual number of days elapsed in a 360-day year) per annum accruing from the Closing Date until the 2022 Notes become due and payable at maturity or upon their conversion, acceleration or by prepayment, and may become due and payable upon the occurrence of an event of default under the 2022 Notes. Any amount of principal or interest on the 2022 Notes which is not paid when due shall bear interest at the rate of the lesser of (i) eighteen percent (18%) per annum or (ii) the maximum amount allowed by law from the due date thereof until payment in full. The 2022 Notes are convertible into shares of Common Stock at the option of each holder of the 2022 Notes from the date of issuance at $9.14 (the “ Conversion Price Maturity Date provided, however Ownership Limitation provided further provided that The 2022 Notes contain customary events of default, which include, among other things, (i) our failure to pay when due any principal or interest payment under the 2022 Notes; (ii) our insolvency; (iii) delisting of our Common Stock; (iv) our breach of any material covenant or other material term or condition under the 2022 Notes; and (v) our breach of any representations or warranties under the 2022 Notes which cannot be cured within five (5) days. Further, events of default under the 2022 Notes also include (i) the unavailability of Rule 144 on or after January 6, 2023; (ii) our failure to deliver the shares of Common Stock to the 2022 Note holder upon exercise by such holder of its conversion rights under the 2022 Note; (iii) our loss of the “bid” price for its Common Stock and/or a market and such loss is not cured during the specified cure periods; and (iv) our failure to complete an uplisting of our Common Stock to any of the Nasdaq Global Market, Nasdaq Capital Market, New York Stock Exchange or NYSE American by February 15, 2023 (an “ Uplist Transaction The 2022 Warrants (i) have an exercise price of $9.94 per share; (ii) have a term of exercise equal to 5 years after their issuance date; (iii) became exercisable immediately after their issuance; and (iv) have a provision preventing the exercisability of such 2022 Warrant if, as a result of the exercise of the 2022 Warrant, the holder, together with its affiliates and any other persons whose beneficial ownership of our Common Stock would be aggregated with the holder’s, would be deemed to beneficially own more than the Ownership Limitation. The holder, upon notice to us, may increase or decrease the Ownership Limitation; provided that (i) the Ownership Limitation may only be increased to a maximum of 9.99% of our Common Stock; and (ii) any increase in the Ownership Limitation will not become effective until the 61st day after delivery of such waiver notice. The number of shares of Common Stock into which each of the 2022 Warrants is exercisable and the exercise price therefor are subject to adjustment as set forth in the 2022 Warrants, including standard antidilution provisions, and adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). In the event of a Fundamental Transaction (as defined in the 2022 Warrants) holders of the 2022 Warrants would be entitled to receive alternate consideration in connection with such Fundamental Transaction, but only to the extent that holders of our Common Stock were entitled to receive the same. Moreover, as long as the 2022 Notes and 2022 Warrants remaining outstanding, upon the issuance of any security in connection with any potential future financing activity on terms more favorable than the existing terms, the Company has an obligation to notify the holders of the 2022 Notes and 2022 Warrants of such more favorable terms and to use best efforts to effect such terms in the 2022 Notes and 2022 Warrants. Finally, because of the Company’s net loss position, the shares underlying the 2022 Notes on an as converted basis are excluded from the calculation of basic and fully diluted earnings per share. Similarly, because of the Company’s net loss position, there was no impact on the calculation of basic and fully diluted earnings per share related to the classification of the 2022 Warrants as participating securities. The Company retained a placement agent in connection with the private placement of $2.4 million of the 2022 Notes to the institutional investors. The Company paid the 2022 Placement Agent 10% of the gross proceeds in the 2022 Placement Agent from certain institutional investors, or $240,000 and we also reimbursed the 2022 Placement Agent approximately $58,000 for non-accountable banking fees, legal fees and other expenses. In addition, we issued 2022 Placement Agent Warrants to purchase an aggregate of 31,510 shares of Common Stock. An additional $1.1 million was raised in connection with the placement of the private placement notes, which included certain accredited investors some of which were Board members and executive officers of the Company. Board member, Laurence Hicks, and executive officers, Terrence W. Norchi and Michael S. Abrams, invested in the 2022 Senior Secured Convertible Notes. The investment made in the 2022 Senior Secured Convertible Notes made by the Board member and executive officers totaled $80,000. In addition, as a part of the 2022 Convertible Notes Offering, certain holders (the “ Series Holders Series Notes Subordinated Notes Closing Date Further, in connection with the 2022 Note Financing, we are required to complete an Uplist Transaction by February 15, 2023 under the terms of the 2022 Notes and Second Notes. If we are unable to complete an Uplist Transaction, then the 2022 Notes and Second Notes will become immediately due and payable and we will be obligated to pay to each holder of the 2022 Notes and Second Notes an amount equal to 125%, multiplied by the sum of the outstanding principal amount of the 2022 Notes and Second Notes plus any accrued and unpaid interest on the unpaid principal amount of the 2022 Notes and Second Notes to the date of payment, plus any default interest and any other amounts owed to the holder, payable in cash or shares of Common Stock. On or before February 14, 2023, the Company secured waivers with all of the holders of the 2022 Notes and Second Notes to extend the deadline to complete an uplist to March 15, 2023. During the three months ended December 31, 2022, the Company recorded interest expense on the 2022 Notes of approximately $499,000 consisting of accrued interest of approximately $127,000 and accretion of original issue discount debt discount and issuance costs of approximately $372,000. Included in the Senior Secured Convertible Notes as of December 31, 2022 is a prepayment of $20,000 in connection to the second closing of the 2022 Notes. The notes issued in connection with the second closing (the “ Second Notes Allocation of Proceeds The Company accounted for the Senior Secured Convertible Notes, the 2022 Warrants, and the 2022 Inducement Shares relating to the aforementioned July 2022 Senior Secured Convertible Promissory Notes in accordance with ASC 470-20-25-2 “Debt” which states that the allocation of the proceeds from the financing shall be based on the relative fair values of the securities issued at the time of the issuance. The 2022 Inducement Shares and the 2022 Warrants, which are indexed to the Company’s stock, are classified within stockholders’ equity (deficit) in the accompanying consolidated financial statements. The allocated value of the 2022 Inducement Shares and the 2022 Warrants are $314,523 and $1,470,133, respectively. The allocated value of the Senior Secured Convertible Notes of $1,740,344 are allocated as long-term liabilities in the accompanying consolidated financial statements. The fair value of the 2022 Placement Agent Warrants of $219,894 are being accounted for as debt issuance costs and are classified within stockholders’ equity (deficit) in the accompanying consolidated financial statements. As of December 31, 2022 and September 30, 2022, the net carrying amount of the Senior Secured Convertible Notes was $2,754,028 and $2,362,273, respectively, with unamortized debt discount and issuance costs of $2,195,752 and $2,567,507, respectively. The 2022 Warrants and the 2022 Placement Agent Warrants were valued as of July 6, 2022 2022 Warrants 2022 Placement Agent Warrants Closing price per share of Common Stock $ 9.98 $ 9.98 Exercise price per share $ 9.94 $ 10.06 Expected volatility 88.44 % 88.44 % Risk-free interest rate 2.96 % 2.96 % Dividend yield — — Remaining expected term of underlying securities (years) 5.0 5.0

Note 12 - Series 1 and Series 2

Note 12 - Series 1 and Series 2 Convertible Notes	3 Months Ended
	Dec. 31, 2022
Series 1 & 2 Convertible Notes [Member]
Notes to Financial Statements
Debt Disclosure [Text Block]	12. SERIES 1 AND SERIES 2 CONVERTIBLE NOTES On June 4, 2020 and November 6, 2020, the Company issued unsecured 10% Series 1 Convertible Notes (“ Series Notes Convertible Notes Conversion Price Holder VWAP In Kind Note Repayment Beginning June 22, 2015 and through June 30, 2015, the Company entered into a series of substantially similar subscription agreements with 20 accredited investors providing for the issuance and sale by the Company to the 2015 Investors, in a private placement, of an aggregate of 71,954 Units at a purchase price of $44.00 per Unit. Each Unit consisted of a share of Common Stock and a Series D Warrant to purchase a share of Common Stock at an exercise price of $50.00 per share at any time prior to the fifth anniversary of the issuance date of the Series D Warrant and the shares issuable upon exercise of the Series D Warrants. On June 3, 2020, the Company entered into an agreement (the “ Agreement Majority Holders Series D Warrants Series J Warrants On June 22, 2020, the Company entered into a Series J Warrant Issuance Agreement (the “ Keyes Sulat Agreement Trust one-year As described in Note 11, above, as a part of the 2022 Convertible Notes Offering, certain holders of the Series Notes agreed to exchange Notes with principal amounts of $600,000 and accrued interest of approximately $100,000 for promissory notes of the Company on substantially similar terms to those of the 2022 Notes (the “ Exchanged Notes Closing Date During the three months ended December 31, 2022 and 2021, the Company recorded interest expense on the Convertible Notes of approximately $25,000 and $40,000, respectively.

Note 13 - Risks and Uncertainti

Note 13 - Risks and Uncertainties - Covid-19 and Geopolitical Conflicts	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
COVID-19 Disclsoure [Text Block]	13. RISKS AND UNCERTAINTIES COVID-19 AND GEOPOLITICAL CONFLICTS The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may be impacted by the outbreak of the COVID-19 or geopolitical conflicts. The Company’s ability to obtain future inventory may be impacted, therefore potentially affecting the Company’s future revenue stream. In addition, the Company has historically and principally funded its operations through debt borrowings, the issuance of convertible debt, and the issuance of units consisting of Common Stock and warrants which may also be impacted by economic conditions beyond the Company’s control as well as uncertainties resulting from geopolitical conflicts, including the recent war in Ukraine. The extent to which the COVID-19 and recent events in Ukraine will impact the global economy and the Company is uncertain and cannot be reasonably measured.

Note 14 - Subsequent Events

Note 14 - Subsequent Events	3 Months Ended
	Dec. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	14. SUBSEQUENT EVENTS The Company evaluated all events or transactions through February 14, 2023, the date which these unaudited interim consolidated financial statements were issued. There were no material subsequent events, other than provided below: On January 13, 2023, the Company filed a Certificate of Change to the Company’s Articles of Incorporation, as amended, with the Secretary of State of the State of Nevada (the “Certificate of Change”), which effected, at 5:00 p.m. Eastern Time on January 17, 2023, a one-for-two-hundred (1:200) reverse stock split (the “Reverse Stock Split”) of both the Company’s issued and outstanding shares of Common Stock, and authorized shares of Common Stock. As a result of the Reverse Stock Split, every two hundred (200) shares of Common Stock issued and outstanding was combined into one (1) share of Common Stock, with a proportionate 1:200 reduction in the Company’s authorized Common Stock. The Reverse Stock Split affected all stockholders uniformly and did not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the Reverse Stock Split would have resulted in some stockholders owning a fractional share. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional shares of Common Stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share and no stockholders received cash in lieu of fractional shares. The Reverse Stock Split did not change the par value of the Common Stock. All outstanding securities entitling their holders to purchase shares of Common Stock or acquire shares of Common Stock, including preferred stock, stock options, restricted stock units, and warrants, were adjusted as a result of the Reverse Stock Split, as required by the terms of those securities. All information included in these consolidated financial statements has been adjusted, on a retrospective basis, to reflect the Reverse Share Split, unless otherwise stated. On January 13, 2023, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Nevada to increase the number of authorized shares of Common stock from 4,000,000 shares to 12,000,000 shares. The increase in the number of authorized shares was approved by the Company’s stockholders on September 29, 2022. As previously disclosed in footnote 11 in this Form 10-Q, the Company entered into a Securities Purchase Agreement, dated July 6, 2022 (“SPA”), with certain institutional and accredited individual investors (collectively, the “Investors”) for the issuance and sale by the Company to the Investors of convertible promissory notes, warrants to purchase shares of common stock, par value $0.001 per share (the “Common Stock”), and shares of Common Stock (the “Convertible Notes Offering”). The first closing of the Convertible Notes Offering occurred on July 6, 2022. On January 18, 2023, the Company entered into Amendment No. 1 to the SPA (the “Amendment” and, together with the SPA, the “Amended SPA”), with certain Investors in connection with the second closing of the Convertible Notes Offering for the issuance and sale by the Company to such Investors of an aggregate of (i) Unsecured Convertible Promissory Notes (each a “Second Note” and collectively, the “Second Notes”) in the aggregate principal amount of $636,000, which includes an aggregate $106,000 original issue discount in respect of the Second Notes; (ii) Warrants (the “Second Warrants”) to purchase an aggregate of 127,968 shares (the “Warrant Shares”) of Common Stock; (iii) 9,598 shares of Common Stock (the “Inducement Shares”) and 6,565 Placement Agent Warrants. The aggregate gross proceeds for the sale of the Second Notes, Second Warrants and Inducement Shares was approximately $530,000, before deducting the placement agent’s fees and other estimated fees and offering expenses payable by the Company. The second closing of the sales of these securities under the Amended SPA occurred on January 18, 2023 (the “Second Closing Date”).

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation Reverse Share Split
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents
Inventory, Policy [Policy Text Block]	Inventories
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets FASB ASC Property, Plant and Equipment
Lessee, Leases [Policy Text Block]	Leases
Income Tax, Policy [Policy Text Block]	Income Taxes Income Taxes
Revenue from Contract with Customer [Policy Text Block]	Revenue Revenue Recognition
Cost of Goods and Service [Policy Text Block]	Cost of Revenue
Research and Development Expense, Policy [Policy Text Block]	Research and Development
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Compensation-Stock Compensation ASC 718 Black-Scholes Model
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Fair Value Measurements and Disclosures
Derivatives, Policy [Policy Text Block]	Derivative Liabilities Derivatives and Hedging ASC 815
Complex Equity Instruments [Policy Text Block]	Complex Financial Instruments Derivatives and Hedging
Subsequent Events, Policy [Policy Text Block]	Subsequent Events
Going Concern [Policy Text Block]	Going Concern Basis of Accounting 2018 SPA 2022 SPA

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (Tables)	3 Months Ended
	Dec. 31, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	Estimated Useful Life (in years) December 31 2022 September 30, 2022 Furniture and fixtures 5 $ 9,357 $ 9,357 Leasehold improvements Life of Lease 8,983 8,983 Computer equipment 3 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 32,375 31,712 Property and equipment, net $ 1,381 $ 2,044

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	3 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, September 30, 2022 2022 Finished Goods $ 85,526 $ 9,063 Goods-in-process 1,326,111 1,405,785 Total $ 1,411,637 $ 1,414,848

Note 6 - Stock-based Compensa_2

Note 6 - Stock-based Compensation (Tables)	3 Months Ended
	Dec. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2022 98,626 $ 52.00 1.46 $ 16,900 Awarded 24,500 $ 6.00 Forfeited/Cancelled (18,801 ) $ 70.00 Outstanding at December 31, 2022 104,325 $ 40.00 1.26 3,900 Vested at December 31, 2022 68,202 $ 54.00 1.50 975 Vested and expected to vest at December 31, 2022 104,325 $ 40.00 1.26 3,900
Nonvested Restricted Stock Shares Activity [Table Text Block]	Three months Ended December 31, 2022 December 31, 2021 Non Vested at September 30, 2022 and 2021 250 2,250 Vested - (375 ) Non Vested at December 31, 2022 and 2021 250 1,875
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	Three months Ended December 31, 2022 December 31, 2021 Non Vested at September 30, 2022 and 2021 $ 18.00 $ 20.00 Vested - (20.00 ) Non Vested at December 31, 2022 and 2021 $ 18.00 $ 20.00

Note 8 - Derivative Liabiliti_2

Note 8 - Derivative Liabilities (Tables)	3 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Fair Value Measurements Using Significant Unobservable Inputs Three Months Ended December 31, 2022 (Level 3) Series G Series H Beginning balance at September 30, 2022 $ 748,275 $ 459,200 Adjustments to estimated fair value — — Ending balance at December 31, 2022 $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs - Three Months Ended December 31, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Issuances — — — Adjustments to estimated fair value — — — Ending balance at December 31, 2021 $ 1,000,000 $ 748,275 $ 459,200
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series G Series H Closing price per share of Common Stock $ 5.20 $ 5.20 Exercise price per share $ 140.00 $ 80.00 Expected volatility 169.62 % 138.58 % Risk-free interest rate 4.76 % 4.57 % Dividend yield — — Remaining expected term of underlying securities (years) 0.43 1.31 Series G Series H Closing price per share of Common Stock $ 3.80 $ 3.80 Exercise price per share $ 140.00 $ 80.00 Expected volatility 132.97 % 122.50 % Risk-free interest rate 4.05 % 4.14 % Dividend yield — — Remaining expected term of underlying securities (years) 0.69 1.57

Note 11 - 2022 Convertible No_2

Note 11 - 2022 Convertible Note Offering (Tables)	3 Months Ended
	Dec. 31, 2022
Notes Tables
Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions [Table Text Block]	2022 Warrants 2022 Placement Agent Warrants Closing price per share of Common Stock $ 9.98 $ 9.98 Exercise price per share $ 9.94 $ 10.06 Expected volatility 88.44 % 88.44 % Risk-free interest rate 2.96 % 2.96 % Dividend yield — — Remaining expected term of underlying securities (years) 5.0 5.0

Note 1 - Description of Busin_2

Note 1 - Description of Business (Details Textual) - $ / shares	Dec. 31, 2022	Sep. 30, 2022
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001

Note 2 - Summary Of Significa_2

Note 2 - Summary Of Significant Accounting Policies (Details Textual)	Jan. 17, 2023
Subsequent Event [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	200

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Depreciation, Total	$ 663	$ 799

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment - Property and Equipment (Details) - USD ($)	15 Months Ended
	Dec. 31, 2022	Sep. 30, 2022
Furniture and fixtures	$ 33,756	$ 33,756
Less – accumulated depreciation	32,375	31,712
Property and equipment, net	$ 1,381	2,044
Furniture and Fixtures [Member]
Furniture and fixtures (Year)	5 years
Furniture and fixtures	$ 9,357	9,357
Leasehold Improvements [Member]
Furniture and fixtures	$ 8,983	8,983
Computer Equipment [Member]
Furniture and fixtures (Year)	3 years
Furniture and fixtures	$ 14,416	14,416
Technology Equipment [Member]
Furniture and fixtures (Year)	5 years
Furniture and fixtures	$ 1,000	$ 1,000

Note 4 - Inventories - Inventor

Note 4 - Inventories - Inventories (Details) - USD ($)	Dec. 31, 2022	Sep. 30, 2022
Finished Goods	$ 85,526	$ 9,063
Goods-in-process	1,326,111	1,405,785
Total	$ 1,411,637	$ 1,414,848

Note 5 - Insurance Premium Fi_2

Note 5 - Insurance Premium Financing (Details Textual) - Insurance Premium Financing [Member] - USD ($)	1 Months Ended
	Jul. 31, 2022	Dec. 31, 2022	Sep. 30, 2022
Debt Instrument, Face Amount	$ 354,000
Debt Instrument, Interest Rate, Stated Percentage	2.99%
Debt Instrument, Periodic Payment, Total	$ 35,000
Short-Term Debt, Total		$ 141,676	$ 247,933

Note 6 - Stock-based Compensa_3

Note 6 - Stock-based Compensation (Details Textual) - USD ($)		12 Months Ended
	Jun. 18, 2013	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2022	Oct. 01, 2021
Common Stock, Shares Authorized		4,000,000		4,000,000
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense		$ 14,000	$ 53,000
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense		88,000	89,000
Employees Directors And Consultants [Member]
Share-Based Payment Arrangement, Expense		102,000	142,000
Non Employee Restricted Shares [Member]
Share-Based Payment Arrangement, Expense		2,000	$ 10,000
The 2013 Plan [Member]
Common Stock, Shares Authorized			170,571		185,571
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized	15,000
Increase In Aggregate Number Of Shares					15,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				50,667
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 295,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		3 years 7 days
The 2013 Plan [Member] | Restricted Stock [Member] | Board Of Directors And Management [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)		20,875
The 2013 Plan [Member] | Restricted Stock [Member] | Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other (in shares)		3,625

Note 6 - Stock-based Compensa_4

Note 6 - Stock-based Compensation - Stock Compensation Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022
Outstanding, Option Shares Outstanding (in shares)	98,626
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 52
Outstanding, Weighted Average Remaining Contractual Term (years) (Year)		1 year 5 months 15 days
Outstanding, Aggregate Intrinsic Value	$ 3,900	$ 16,900
Awarded, Option Shares Outstanding (in shares)	24,500
Awarded, Weighted Average Exercise Price (in dollars per share)	$ 6
Forfeited/Cancelled, Option Shares Outstanding (in shares)	(18,801)
Forfeited/Cancelled, Weighted Average Exercise Price (in dollars per share)	$ 70
Outstanding, Option Shares Outstanding (in shares)	104,325	98,626
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 40	$ 52
Vested, Option Shares Outstanding (in shares)	68,202
Vested, Weighted Average Exercise Price (in dollars per share)	$ 54
Vested, Weighted Average Remaining Contractual Term (years) (Year)	1 year 6 months
Vested, Aggregate Intrinsic Value	$ 975
Vested and expected to vest, Option Shares Outstanding (in shares)	104,325
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)	$ 40
Vested and expected to vest,Weighted Average Remaining Contractual Term (years) (Year)	1 year 3 months 3 days
Vested and expected to vest, Aggregate Intrinsic Value	$ 3,900

Note 6 - Stock-based Compensa_5

Note 6 - Stock-based Compensation - Restricted Stock Activity (Details) - shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Restricted Stock [Member]
Non Vested, shares (in shares)		2,250
The 2013 Plan [Member]
Non Vested, shares (in shares)	250
Vested, shares (in shares)	0	(375)
Non Vested, shares (in shares)	250	1,875

Note 6 - Stock-based Compensa_6

Note 6 - Stock-based Compensation - Restricted Stock Weighted Average Grant Date Fair Value (Details) - $ / shares	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Non Vested, weighted average fair value (in dollars per share)	$ 18	$ 20
Vested, weighted average fair value (in dollars per share)	0
Non Vested, weighted average fair value (in dollars per share)	$ 18	20
Restricted Stock [Member]
Vested, weighted average fair value (in dollars per share)		$ 20

Note 7 - Registered Direct Of_2

Note 7 - Registered Direct Offerings (Details Textual)						12 Months Ended
	Dec. 31, 2022 shares	Feb. 17, 2021 shares	May 12, 2019 item $ / shares shares	Jun. 28, 2018 item $ / shares shares	Feb. 20, 2017 $ / shares shares	Sep. 30, 2022 shares	Sep. 30, 2016 USD ($)
Shelf Registration Statement, Maximum Amount Authorized | $							$ 50,000,000
Stock Issued During Period, Shares, New Issues	4,000,000	215,625
Class Of Series F Warrant [Member]
Percentage of Warrants Per Unit					0.55
Class Of Warrant Or Right Acquired Upon Exercise						34,013
Series F Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 150
Class of Warrant or Right, Expired During Period (in shares)						27,958
Class Of Series G Warrant [Member]
Percentage of Warrants Per Unit				0.75
Class Of Warrant Or Right Acquired Upon Exercise						43,077
Class Of Series H Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 80
The 2017 SPA [Member]
Stock Issued During Period, Shares, New Issues					50,833
Shares Issued, Price Per Share | $ / shares					$ 120
The 2018 SPA [Member]
Stock Issued During Period, Shares, New Issues				45,350
Shares Issued, Price Per Share | $ / shares				$ 100
Number Of Accredited Investors | item				8
Registered Direct Offering 2018 [Member] | Class Of Series G Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 140
The 2019 SPA [Member]
Stock Issued During Period, Shares, New Issues			43,077
Shares Issued, Price Per Share | $ / shares			$ 65
Number Of Accredited Investors | item			5

Note 8 - Derivative Liabiliti_3

Note 8 - Derivative Liabilities (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Derivative Warrant Liability [Member]
Derivative Liability, Total	$ 1,628,113
Fair Value Adjustment of Derivatives	$ 0	$ 0
Series F Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	$ 36
Series G Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	22
Series H Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	$ 10.66

Note 8 - Derivative Liabiliti_4

Note 8 - Derivative Liabilities - Fair Value of Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member] - Derivative Financial Instruments, Liabilities [Member] - USD ($)	3 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Series G Warrant Derivative [Member]
Beginning balance at September 30, 2022	$ 748,275	$ 748,275
Beginning balance at September 30, 2021	748,275	748,275
Adjustments to estimated fair value	0	0
Issuances		0
Ending balance at December 31, 2022	748,275	748,275
Series F Warrant Derivative [Member]
Beginning balance at September 30, 2022		1,000,000
Beginning balance at September 30, 2021		1,000,000
Adjustments to estimated fair value		0
Issuances		0
Ending balance at December 31, 2022		1,000,000
Series H Warrant Derivative [Member]
Beginning balance at September 30, 2022	459,200	459,200
Beginning balance at September 30, 2021	459,200	459,200
Adjustments to estimated fair value	0	0
Issuances		0
Ending balance at December 31, 2022	$ 459,200	$ 459,200

Note 8 - Derivative Liabiliti_5

Note 8 - Derivative Liabilities - Derivative Liability Value Assumptions (Details) - Derivative Financial Instruments, Liabilities [Member]	Dec. 31, 2022	Sep. 30, 2022
Measurement Input, Exercise Price [Member] | Series G Warrant Derivative [Member]
Derivative Liability, Measurement Input		140
Measurement Input, Exercise Price [Member] | Series H Warrant Derivative [Member]
Derivative Liability, Measurement Input	80	80
Measurement Input, Exercise Price [Member] | Series G Warrant [Member]
Derivative Liability, Measurement Input	140
Measurement Input, Share Price [Member] | Series G Warrant Derivative [Member]
Derivative Liability, Measurement Input	5.20
Measurement Input, Share Price [Member] | Series H Warrant Derivative [Member]
Derivative Liability, Measurement Input	5.20
Measurement Input, Price Volatility [Member] | Series G Warrant Derivative [Member]
Derivative Liability, Measurement Input	1.6962	1.3297
Measurement Input, Price Volatility [Member] | Series H Warrant Derivative [Member]
Derivative Liability, Measurement Input	1.3858	1.2250
Measurement Input, Risk Free Interest Rate [Member] | Series G Warrant Derivative [Member]
Derivative Liability, Measurement Input	4.76	0.0405
Measurement Input, Risk Free Interest Rate [Member] | Series H Warrant Derivative [Member]
Derivative Liability, Measurement Input	4.57	0.0414
Measurement Input, Expected Dividend Rate [Member] | Series G Warrant Derivative [Member]
Derivative Liability, Measurement Input		0
Measurement Input, Expected Dividend Rate [Member] | Series H Warrant Derivative [Member]
Derivative Liability, Measurement Input		0
Measurement Input, Expected Term [Member] | Series G Warrant Derivative [Member]
Derivative Liability, Measurement Input	0.43	0.0069
Measurement Input, Expected Term [Member] | Series H Warrant Derivative [Member]
Derivative Liability, Measurement Input	1.31	0.0157
Measurement Input, Inception Discount Rate [Member] | Series G Warrant Derivative [Member]
Derivative Liability, Measurement Input	0
Measurement Input, Inception Discount Rate [Member] | Series H Warrant Derivative [Member]
Derivative Liability, Measurement Input	0

Note 9 - October 2019 Registe_2

Note 9 - October 2019 Registered Direct Offering (Details Textual)	Dec. 31, 2022 shares	Feb. 17, 2021 shares	Oct. 18, 2019 USD ($) $ / shares shares	Oct. 10, 2019 USD ($)	Sep. 30, 2022 shares
Stock Issued During Period, Shares, New Issues	4,000,000	215,625
Series I Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 44
October 2019 Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 43.75
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,358
Warrants and Rights Outstanding, Term			5 years
Class of Series I Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					71,429
Proceeds from Subscribed, Unissued Common Stock and Warrants | $				$ 2,500,000
Payments of Stock Issuance Costs | $				$ 158,000
Class of Series I Warrant [Member] | Minimum [Member]
Percentage of Fee on Gross Proceeds of Warrants			0.060
Class of Series I Warrant [Member] | Maximum [Member]
Percentage of Fee on Gross Proceeds of Warrants			0.082
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					5,358
October 2019 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues			71,429
Shares Issued, Price Per Share | $ / shares			$ 35
Registered Direct Offering October 2019 [Member]
Stock Issued During Period, Shares, New Issues			71,429
Proceeds from Subscribed, Unissued Common Stock and Warrants | $			$ 2,500,000
Payments of Financing Costs, Total | $			333,000
Payments of Stock Issuance Costs | $			$ 158,000

Note 10 - 2021 Registered Dir_2

Note 10 - 2021 Registered Direct Offering (Details Textual) - USD ($)	Dec. 31, 2022	Feb. 17, 2021	Feb. 11, 2021
Stock Issued During Period, Shares, New Issues	4,000,000	215,625
Series K Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	161,719		161,719
Warrants and Rights Outstanding, Term			5 years 6 months
Placement Agent 2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	16,172		16,172
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 40
Warrants and Rights, Percent of Stock Oustanding Callable			7.50%
The 2021 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues			215,625
Shares Issued, Price Per Share			$ 32
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 34
Proceeds from Issuance or Sale of Equity, Total			$ 6,900,000
Payments of Stock Issuance Costs			700,000
The 2021 Registered Direct Offering [Member] | Non-accountable Expense Fee [Member]
Securities Purchase Agreement, Potential Fees			10,000
The 2021 Registered Direct Offering [Member] | Fees and Expenses of Legal Counsel and Other Out-of-pocket Expenses [Member]
Securities Purchase Agreement, Potential Fees			50,000
The 2021 Registered Direct Offering [Member] | Clearing Expenses [Member]
Securities Purchase Agreement, Potential Fees			$ 10,000
The 2021 Registered Direct Offering [Member] | Participating Investors [Member]
Securities Purchase Agreement, Cash Placement Fee			7.50%
The 2021 Registered Direct Offering [Member] | Certain Investors With Pre-existing Relationships [Member]
Securities Purchase Agreement, Cash Placement Fee			6%

Note 11 - 2022 Convertible No_3

Note 11 - 2022 Convertible Note Offering (Details Textual)				12 Months Ended
	Dec. 31, 2022 USD ($) shares	Jul. 07, 2022 USD ($) $ / shares shares	Feb. 17, 2021 shares	Sep. 30, 2022 USD ($) shares	Nov. 06, 2020 USD ($) $ / shares	Jun. 04, 2020 USD ($) $ / shares
Stock Issued During Period, Shares, New Issues | shares	4,000,000		215,625
Percentage of Principal Amount		15%
Proceeds from Issuance of Convertible Notes, Common Stock and Warrants, Gross		$ 3,500,000
Debt Issuance Costs, Gross		775,000
Placement Agents Fees		$ 555,000
Inducement Shares 2022 [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 314,523
Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues | shares		63,833
Notes 2022 [Member]
Proceeds from Issuance of Private Placement		$ 2,400,000
Placement Agent 2022 [Member]
Percentage of Gross Proceeds from Issuance of Private Placement				1,000%
Reimbursement of Non-accountable Banking Fees				$ 58,000
Placement Agent 2022 [Member] | Certain Investors [Member]
Payments of Stock Issuance Costs				240,000
Private Placement Notes [Member]
Proceeds from Issuance of Private Placement		$ 1,100,000
Warrant Shares [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		425,554
Placement Agent Warrant 2022 [Member]
Warrants and Rights Outstanding		$ 220,000
Warrant 2022 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 9.94
Long-Term Debt, Total				$ 1,470,133
Warrant 2022 [Member] | Maximum [Member]
Ownership Limitation		9.99%
Placement Agent 2022 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				31,510
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				5,358
Warrants and Rights Outstanding				$ 219,894
Notes 2022 [Member]
Debt Instrument, Face Amount		$ 4,230,000
Debt Instrument, Unamortized Discount, Total		$ 705,000
Debt Instrument, Interest Rate, Stated Percentage		10%
Debt Instrument, Interest Rate for Amount of Principal or Interest Not Paid When Due		18%
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 9.14
Debt Instrument, Convertible, Number of Equity Instruments		76,563
Interest Payable				127,000
Interest Expense, Debt, Total				499,000
Accretion of Debt Discount				372,000
Prepayment Included in Convertible Debt	$ 20,000
Long-Term Debt, Total	2,754,028			2,362,273
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total	2,195,752			2,567,507
Notes 2022 [Member] | Minimum [Member]
Ownership Limitation		4.99%
Notes 2022 [Member] | Maximum [Member]
Ownership Limitation		9.99%
Senior Secured Convertible Notes [Member] | Board Member and Executive Officer [Member]
Proceeds from Convertible Debt				$ 80,000
Series 1 Convertible Notes [Member]
Debt Instrument, Face Amount						$ 550,000
Debt Instrument, Interest Rate, Stated Percentage		10%				10%
Debt Instrument, Convertible, Conversion Price | $ / shares						$ 54
Series 1 Convertible Notes [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares						$ 64
Series 2 Convertible Notes [Member]
Debt Instrument, Face Amount					$ 1,050,000
Debt Instrument, Convertible, Conversion Price | $ / shares					$ 50
Convertible Debt, Total		$ 600,000
Interest Payable		$ 100,000
Debt Instrument, Failure to Complete Uplist Transaction Fee, Percentage of Outstanding Principal		125%
Senior Secured Convertible Promissory Notes [Member]
Long-Term Debt, Total	$ 1,740,344

Note 11 - 2022 Convertible No_4

Note 11 - 2022 Convertible Note Offering - Summary of Valuation Assumptions for Warrants (Details)	Jul. 06, 2022 $ / shares
Investor Warrants [Member]
Closing price per share of Common Stock (in dollars per share)	$ 9.98
Investor Warrants [Member] | Measurement Input, Exercise Price [Member]
Exercise price per share	9.94
Investor Warrants [Member] | Measurement Input, Price Volatility [Member]
Exercise price per share	0.8844
Investor Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Exercise price per share	0.0296
Investor Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Exercise price per share	0
Investor Warrants [Member] | Measurement Input, Expected Term [Member]
Exercise price per share	5
Placement Agent Warrants [Member]
Closing price per share of Common Stock (in dollars per share)	$ 9.98
Placement Agent Warrants [Member] | Measurement Input, Exercise Price [Member]
Exercise price per share	10.06
Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]
Exercise price per share	0.8844
Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Exercise price per share	0.0296
Placement Agent Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Exercise price per share	0
Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member]
Exercise price per share	5

Note 12 - Series 1 and Series_2

Note 12 - Series 1 and Series 2 Convertible Notes (Details Textual)					12 Months Ended
	Jul. 06, 2022 USD ($)	Jun. 22, 2020 USD ($) shares	Jun. 03, 2020 USD ($) shares	Jun. 30, 2015 $ / shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Jul. 07, 2022 USD ($)	Jun. 22, 2022 $ / shares	Nov. 06, 2020 USD ($) $ / shares shares	Jun. 04, 2020 USD ($) $ / shares
Series 2 Notes Converted to Senior Secured Convertible Notes [Member]
Debt Conversion, Original Debt, Amount	$ 699,780
Series D Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 50
Series D Warrants [Member]
Proceeds from Warrant Exercises		$ 82,000	$ 850,000
Class of Warrant or Right, Warrants Exercised | shares		2,273	23,636
Series J Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 50			$ 50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		1,705			17,727				16,875
Warrants and Rights Outstanding, Term					1 year
Private Placement [Member]
Issuance or Sale of Equity, Number of Units				71,954
Shares Issued, Price Per Share | $ / shares				$ 44
Series 1 Convertible Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage							10%			10%
Debt Instrument, Face Amount										$ 550,000
Debt Instrument, Convertible, Conversion Price | $ / shares										$ 54
Series 1 Convertible Notes [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares										$ 64
Series 2 Convertible Notes [Member]
Debt Instrument, Face Amount									$ 1,050,000
Debt Instrument, Convertible, Conversion Price | $ / shares									$ 50
Convertible Debt, Total							$ 600,000
Interest Payable							$ 100,000
Series 1 & 2 Convertible Notes [Member]
Interest Expense, Debt, Total					$ 25,000	$ 40,000

Note 14 - Subsequent Events (De

Note 14 - Subsequent Events (Details Textual)	Jan. 18, 2023 USD ($) shares	Jan. 17, 2023	Jan. 13, 2023 $ / shares shares	Dec. 31, 2022 $ / shares shares	Jul. 07, 2022 USD ($) shares	Feb. 17, 2021 shares	Sep. 30, 2022 $ / shares shares
Stock Issued During Period, Shares, New Issues				4,000,000		215,625
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares				$ 0.001			$ 0.001
Proceeds from Issuance of Convertible Notes, Common Stock and Warrants, Gross | $					$ 3,500,000
Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues					63,833
Warrant Shares [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					425,554
Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							5,358
Notes 2022 [Member]
Debt Instrument, Face Amount | $					$ 4,230,000
Debt Instrument, Unamortized Discount, Total | $					$ 705,000
Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues			12,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.001
Proceeds from Issuance of Convertible Notes, Common Stock and Warrants, Gross | $	$ 530,000
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues	9,598
Subsequent Event [Member] | Warrant Shares [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	127,968
Subsequent Event [Member] | Placement Agent Warrants [Member]
Class of Warrant or Right, Outstanding	6,565
Subsequent Event [Member] | Notes 2022 [Member]
Debt Instrument, Face Amount | $	$ 636,000
Debt Instrument, Unamortized Discount, Total | $	$ 106,000
Subsequent Event [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		200